BioNTech and Ryvu Therapeutics enter partnership
Research collaboration for several small molecule immunotherapy programs
02-Dec-2022 -
BioNTech SE and Ryvu Therapeutics S.A., a clinical-stage company developing oncology therapeutics announced that the companies have entered into a multi-target research collaboration for several small molecule immunotherapy programs as well as an exclusive license agreement for Ryvu’s STING ...
BioNTech
cancer immunotherapies
immuno-oncology
+1